drug

**Drug Discovery AI Generative Models** is **applying deep learning to design novel drug molecules with desired properties, accelerating discovery and reducing costs in pharmaceutical development** — AI dramatically speeds drug design. Generative models create chemical space. **Molecular Representations** SMILES strings: text representation of molecules (e.g., CCO = ethanol). Advantages: trainable with NLP methods. Limitations: syntax constraints. Molecular graphs: atoms/bonds as nodes/edges. Graph neural networks naturally process graphs. **Graph Neural Networks for Molecules** message passing neural networks process molecular graphs. Node features (atom type, charge), edge features (bond type). Permutation invariant: output independent of atom ordering. **Generative Adversarial Networks (GANs)** GAN generator creates new molecules, discriminator distinguishes real from generated. Adversarial training balances generation and realism. **Variational Autoencoders (VAE)** encoder maps molecules to latent space, decoder generates molecules from latent codes. Latent space continuous—interpolation between molecules. **Reinforcement Learning for Generation** treat molecule generation as sequential decision: at each step, choose atom/bond to add. RL reward based on desired properties (drug-likeness, activity, synthesis feasibility). **Property Prediction** neural networks predict molecular properties (binding affinity, solubility, toxicity). Trained on experimental data. Guide generation towards favorable properties. **Scaffold Hopping** find new scaffolds maintaining desired properties. Graph-based methods constrain generation to scaffold class. **Multi-Objective Optimization** design molecules optimizing multiple objectives: potency, selectivity, safety, synthesis cost, off-target effects. Pareto frontier approaches. **Synthesis Feasibility** generated molecules might be impossible or expensive to synthesize. Machine learning models predict synthesis difficulty. Incorporate feasibility into generation objective. **SMILES Tokenization** break SMILES into tokens (atoms, bonds), apply seq2seq models. Hybrid approach combining text and graph. **Transformer Models** seq2seq transformers generate SMILES conditioned on desired properties. Encode property, decode SMILES. Attention visualizes which properties influence which atoms. **Physics-Informed Models** incorporate domain knowledge: valency constraints, periodic table properties. Reduces invalid molecule generation. **Active Learning** iteratively select most informative molecules to synthesize/test. Reduce experimental cost. **Transfer Learning** pretrain on large unlabeled molecule databases, finetune on drug discovery task. **Molecular Similarity** find similar molecules to hits for lead optimization. Fingerprints, graph similarity, embedding distance. **Known Drug Database Integration** leverage existing drugs as context. Don't rediscover known actives. Novelty metrics. **Lead Optimization** improve hit compounds: increase potency, selectivity, reduce toxicity, improve ADMET (absorption, distribution, metabolism, excretion, toxicity). Structure-activity relationship (SAR) learning. **Fragment-Based Generation** generate molecules from chemical fragments. Ensures generated molecules decompose into known fragments. **Natural Product Generation** generative models trained on natural products mimic natural chemistry. Generate biologically-plausible molecules. **Enzyme Engineering** design mutations improving enzyme function. Graph representations capture protein structure. **Clinical Validation** AI-designed molecules eventually tested in animals then humans. Validate AI enables real drug discovery. **Applications** cancer drugs, antibiotics (against resistant bacteria), rare genetic diseases, personalized medicine. **Timeline Acceleration** AI potentially reduces drug discovery from 10+ years to significantly faster. **Drug discovery AI transforms pharmaceutical industry** enabling faster, cheaper drug development.